Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing

Novo Nordisk offers an attractive 3.5% dividend yield backed by a shifting business model focused on volume-driven growth in GLP-1 weight-loss drugs. Despite 2026 being a transition year with pricing pressures and generic competition, the company's strong pill formulation demand and solved supply issues position it well. The stock trades below five-year valuation averages, making it appealing for dividend investors seeking recurring income similar to its insulin business.